<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="221870">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00194987</url>
  </required_header>
  <id_info>
    <org_study_id>0102004801</org_study_id>
    <nct_id>NCT00194987</nct_id>
  </id_info>
  <brief_title>A Trial of Antenatal Treatment of Alloimmune Thrombocytopenia</brief_title>
  <official_title>A Randomized Multicenter Trial of Antenatal Treatment of Alloimmune Thrombocytopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>New York Presbyterian Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study are to provide medical management by giving treatment to the
      mother that will bring up the fetal platelet count and to minimize the number of invasive
      procedures to the fetus (which may result in serious fetal injuries).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2001</start_date>
  <completion_date type="Anticipated">June 30, 2017</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To raise the platelet count of affected fetus.</measure>
    <time_frame>20-30 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Alloimmune Thrombocytopenia</condition>
  <condition>Fetal Alloimmune Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IVIG (Intravenous Immunoglobulin)</intervention_name>
    <description>one to two mg per kg once-twice weekly</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Pregnant women are eligible for inclusion into the Very High Risk Group if they:

          -  are PLA-1 negative and have known platelet incompatibility with their fetus

          -  have had a previous child who suffered an antenatal hemorrhage prior to 28 weeks
             gestation (as best as could be estimated)

          -  are less than 19 weeks gestation

        Pregnant women are eligible for inclusion into the High Risk Group if they:

          -  are PLA-1 negative and have known platelet incompatibility with the fetus

          -  have had a previous child who suffered an antenatal hemorrhage after 28 weeks
             gestation (as best as could be estimated)

          -  are between 12-30 weeks gestation

        Pregnant women are eligible for inclusion into the Standard Risk Group if they:

          -  are PLA-1 negative and have known platelet incompatibility with the fetus

          -  have not had a previous child who suffered an antenatal hemorrhage

          -  are between 20-30 weeks gestation

        Exclusion Criteria:

        Women are not eligible for inclusion into the Very High Risk Group if they:

          -  have had a previous child who suffered an antenatal hemorrhage after 28 weeks
             gestation

          -  are greater than 19 weeks gestation

        Women are not eligible for inclusion into the High Risk Group if they:

          -  have had a previous child who suffered an antenatal hemorrhage prior to 28 weeks
             gestation

          -  are greater than 30 weeks gestation

        Women are not eligible for inclusion into the Standard Risk Group if they:

          -  have had a previous child who suffered an antenatal hemorrhage

          -  are greater than 30 weeks gestation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James B Bussel, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>James B. Bussel, M.D.</last_name>
    <phone>212-746-3474</phone>
    <email>jbussel@med.cornell.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arelys M Rocha, BS, BA, CCRC</last_name>
    <phone>212-746-3423</phone>
    <email>arr7008@med.cornell.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>New York Presbyterian Hospital-Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James B. Bussel, M.D.</last_name>
      <phone>212-746-3474</phone>
      <email>jbussel@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>James B Bussel, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 30, 2017</lastchanged_date>
  <firstreceived_date>September 13, 2005</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alloimmune thrombocytopenia</keyword>
  <keyword>Fetal alloimmune thrombocytopenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
